Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial

•We hypothesized that eicosapentaenoic acid (EPA) added to statin may alter high-density lipoprotein (HDL) heterogeneity.•Additional EPA therapy decreased the HDL3 level and increased the HDL2/HDL3 ratio.•The increase in EPA/arachidonic acid (AA) ratio may be a predictor of elevation of the HDL2/HDL...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of cardiology 2020-03, Vol.75 (3), p.282-288
Hauptverfasser:	Tani, Shigemasa, Matsuo, Rei, Yagi, Tsukasa, Matsumoto, Naoya
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Coronary artery disease Coronary Artery Disease - blood Coronary Artery Disease - drug therapy Eicosapentaenoic Acid - therapeutic use Eicosapentaenoic acid/arachidonic acid ratio Female High-density lipoprotein heterogeneity Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Lipoproteins, HDL - blood Male Middle Aged Statin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!